- Touchlight, a biotechnology company pioneering enzymatic DNA production, announced a non-exclusive patent license agreement with Pfizer Inc (NYSE:PFE).
- The pharma giant has inked a non-exclusive license agreement with Touchlight to utilize its enzymatic “doggybone DNA” (dbDNA) in the manufacturing process for mRNA vaccines, therapeutics, and gene therapies.
- Under the deal, Touchlight will receive an upfront payment, plus clinical and commercial milestone payments and royalties upon potential commercialization.
- Specific financial details were not disclosed.
- Touchlight’s patented dbDNA technology is “uniquely positioned” for the rapid manufacture of DNA for vaccines and therapeutics, the company says.
- The platform is a minimal, lineal, covalently closed structure that eliminates bacterial sequences, Touchlight adds. According to Touchlight, this enables “unprecedented” speed and scale in manufacturing.
- Price Action: PFE shares are up 1.70% at $52.52 during the market session on the last check Wednesday.
Pfizer And BioNTech Receive Positive CHMP Opinion For Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster In European Union
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
The Omicron BA.1-adapted bivalent COVID-19 vaccine combines
